Seer (SEER) Proxy filing summary

Executive summary

• Annual meeting scheduled for July 28, 2026, with voting rights for shareholders of record as of May 29, 2026.

• Board urges shareholders to vote for its seven nominated directors to support ongoing strategic execution and long-term value creation.

• Company emphasizes its leadership in deep, unbiased proteomics and ongoing commercial and scientific advancements.

• Forward-looking statements highlight expectations for growth, commercial opportunity, and continued innovation.

Voting matters and shareholder proposals

• Shareholders are asked to vote for seven board nominees on the BLUE proxy card.

• Competing nominees from Radoff-JEC Group are criticized for lacking relevant expertise and independence.

• Board warns that electing dissident nominees could disrupt momentum and risk long-term value.

Board of directors and corporate governance

• Board consists of seven highly qualified, independent directors with significant industry experience.

• Current board collectively owns 17% of outstanding shares as of May 11, 2026.

• Board is described as highly engaged and purpose-built for strategic oversight.